Comparative Effectiveness Study for Bipolar Disorder

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Andrew A. Nierenberg, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01331304
First received: April 6, 2011
Last updated: May 23, 2014
Last verified: May 2014

April 6, 2011
May 23, 2014
September 2010
April 2013   (final data collection date for primary outcome measure)
  • Clinical Global Impression-Efficacy Index (CGI-EI) [ Time Frame: Average 6 month score minus Average baseline score ] [ Designated as safety issue: Yes ]
    The CGI-EI integrates benefits and harms and yields a score that can be compared across interventions. It is made up of 2 subscales: therapeutic effects and side effects. Each rating is on a scale from 1 to 4. To combine these two subscales into the CGI-EI we report as our primary outcome, we subtracted the side effects subscale from the therapeutic effects subscale. Thus, the CGI-EI we report ranges the integers from -3 to +3 (i.e. possible scores are -3,-2,-1,0,1,2,3). A score of -3 is the most burdensome side effect score (4) and the least therapeutic effect score (1) and a score of +3 is the least burdensome side effect score (1) and the highest therapeutic effect score (4). Higher CGI-EI signifies better outcome (minimal side effects, maximal therapeutic effect). Lower CGI-EI signifies worse outcome (maximal side effects, minimal therapeutic effect).To compute CGI-EI score, we subtract the side effect score from the therapeutic effect score.
  • Necessary Clinical Adjustments [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
    Necessary Clinical Adjustment (NCA): The Medication Recommendation Tracking Form was developed and successfully implemented in a previous study to capture recommended medication changes at each study visit 17. Clinicians record dosage changes, missed doses, new medications added or discontinued, and specify the reason for each change. Any change in psychotropic medications, or medications used to treat side effects, is coded along with the reason for the change. NCAs include those changes made for lack of effectiveness or intolerance, but not changes for planned dose titrations.
Clinical Global Impression-Efficacy Index (CGI-EI) [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
The CGI-EI integrates benefits and harms and yields a score that can be compared across interventions.
Complete list of historical versions of study NCT01331304 on ClinicalTrials.gov Archive Site
  • Risk of Cardiovascular Disease - Framingham Risk Score [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    The Framingham risk score captures the classic risk factors for cardiovascular disease, including age, sex, systolic blood pressure, total and high density lipoprotein cholesterol, diabetes mellitus, and smoking. The Framingham risk score is used as a simple predictive tool to determine 10-year (short term) risk for developing cardiovascular disease (CHD).
  • Longitudinal Interval Follow up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The LIFE-RIFT asses the extent to which psychopathology has impacted current functioning in work, household chores, interpersonal relationships with partner, family, and friends, recreational activities, and life, satisfaction, leisure activities and social relationships.
  • Risk of cardiovascular disease - Framingham Risk Score [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    The Framingham risk score captures the classic risk factors for cardiovascular disease, including age, sex, systolic blood pressure, total and high density lipoprotein cholesterol, diabetes mellitus, and smoking. The Framingham risk score is used as a simple predictive tool to determine 10-year (short term) risk for developing cardiovascular disease (CHD).
  • Longitudinal Interval Follow up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The LIFE-RIFT asses the extent to which psychopathology has impacted current functionging in work, household chores, interpersonal relationships with partner, family, and friends, recreational activities, and life, satisfaction, leisure activities and social relationships.
Not Provided
Not Provided
 
Comparative Effectiveness Study for Bipolar Disorder
Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer And a Classic Mood Stabilizer for Bipolar Disorder

The purpose of this study is to compare the effectiveness of lithium and quetiapine for the treatment of individuals with bipolar disorder.

Mood stabilizers, medications that prevent future mood episodes, are the foundation for treatment of bipolar disorder. While all published bipolar disorder treatment guidelines recommend that pharmacotherapy should include mood stabilizers for long-term maintenance treatment, no randomized comparative effectiveness studies have examined the real-world advantages and disadvantages of the newer second generation antipsychotic (SGA) mood stabilizers compared to the classic mood stabilizers, such as lithium (Li). No studies have looked at the effectiveness of SGAs compared to mood stabilizers when used in the context of other medications required to manage bipolar patients, since bipolar disorder patients take a median of 3 medications for optimal outcomes. Quetiapine (QTP) is the most extensively studied, broadly efficacious and the most widely prescribed SGA for bipolar disorder. The classic mood stabilizer Li has the largest evidence base for treating bipolar disorder, but has been largely supplanted by the SGAs.

Thus, this study compares symptomatic benefits and adverse effect burden between a QTP foundation with adjunctive personalized treatments (QTP+APT) and a mood stabilizer foundation consisting of Li with APT (Li+APT). APT will include any other medication needed with the following exceptions: the QTP+APT cannot receive Li and the Li+APT group cannot receive an antipsychotic. If, however, participants clinically require a switch to, or the addition of any other SGA or mood stabilizer, then those medications can be added as a rescue strategy that will be carefully recorded. Consistent with an effectiveness trial, participants will be able to continue in the study if they require a rescue treatment. The specific plan is a randomized, open, two arm, comparative effectiveness study of QTP+APT vs. Li+APT treatment for 6 months across 10 sites.

In summary, this comparative effectiveness study compares fundamentally different acute and continuation treatments for bipolar disorder. The investigators address the key question of whether to use a prototypical mood stabilizing SGA (i.e., QTP) or the classical mood stabilizer Li as the foundational treatment in the context of other necessary adjunctive personalized treatments (APT).

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Bipolar Disorder
  • Drug: Lithium
    600-900mg per day over 6 months
    Other Name: Lithoboid, Eskalith
  • Drug: Quetiapine
    100-800mg a day over 6 months
    Other Name: Seroquel
  • Li + APT
    Study participants will take lithium in addition to any other medications recommended by the study physician.
    Intervention: Drug: Lithium
  • QTP + APT
    Study participants will take quetiapine in addition to any other medications recommended by the study physician.
    Intervention: Drug: Quetiapine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
482
September 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Meets DSM-IV criteria for BD I or II, which is the primary focus of treatment
  2. Able to give written informed consent
  3. Age > to 18 years and < 68 years
  4. Women of child bearing potential must agree to use adequate contraception (e.g. oral contraceptives, intrauterine device, barrier methods, or total abstinence from intercourse; Depo Provera is acceptable if it is started 3 months prior to enrollment), inform their doctor at the earliest possible time of their plans to conceive, and to understand the risks of lithium and other study treatments to the fetus and infant
  5. Currently symptomatic, as defined as a Clinical Global Impression - Bipolar Disorder Overall Severity (CGI-BP-S) score of at least 3 (mild)
  6. If currently taking an SGA, participants would be required to be willing to either discontinue or switch to QTP
  7. Willing to be randomized to either QTP+APT or Li+APT.

Exclusion Criteria:

  1. Unwilling or unable to comply with study requirements
  2. If maintained on thyroid medication must be euthyroid for at least 1 month before Visit 1
  3. Patients who have had intolerable side effects with QTP or Li
  4. Patients whose clinical status requires inpatient care
  5. Drug/alcohol dependence within the past 30 days
  6. Pregnancy as determined by urine pregnancy test or breastfeeding
  7. History of nonresponse to Li at a serum level of ≥ 1.0 mEq/L ≥ 8 weeks
  8. History of nonresponse to QTP at doses of at least 600 mg ≥ 8 weeks.
Both
18 Years to 68 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01331304
R01 HS019371-01
Yes
Andrew A. Nierenberg, MD, Massachusetts General Hospital
Massachusetts General Hospital
Agency for Healthcare Research and Quality (AHRQ)
Principal Investigator: Andrew A Nierenberg, MD Massachusetts General Hospital
Massachusetts General Hospital
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP